TScan Therapeutics (TCRX) Preferred Stock Liabilities (2020 - 2021)
TScan Therapeutics' (TCRX) quarterly Preferred Stock Liabilities came in at $159.4 million in Q2 2021, up 167.11% year-on-year from $59.7 million in Q2 2020, and little changed on a QoQ basis from $159.4 million in Q1 2021.
TScan Therapeutics (TCRX) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
TScan Therapeutics (TCRX) has 2 years of Preferred Stock Liabilities data on file, last reported at $159.4 million in Q2 2021.
- On a quarterly basis, Preferred Stock Liabilities rose 167.11% year-over-year to $159.4 million in Q2 2021; TTM through Jun 2021 was $159.4 million, a 167.11% increase from a year earlier, with the FY2020 full-year figure at $59.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2021 stood at $159.4 million, roughly flat from $159.4 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for TCRX reached as high as $159.4 million in Q1 2021 and fell as low as $59.7 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | TScan Therapeutics | 100.59 Mn | -27.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 159.41 Mn |
| Mar 31, 2021 | 159.41 Mn |
| Dec 31, 2020 | 59.68 Mn |
| Sep 30, 2020 | 59.68 Mn |
| Jun 30, 2020 | 59.68 Mn |